PTGX Protagonist Corp: Net earnings per share for the last 12 months

Patent protection and support from industry behemoths mitigate peptide development risks amid fierce competition. Historical EPS YoY TTM dynamics illustrate the current trend, where 576.60 describes the metric's current status. Protagonist Therapeutics (PTGX) generates revenue based on licensing payments and royalties from the sale of innovative drugs for patients with blood pathologies.
PTGX (Protagonist Therapeutics Inc): analytical breakdowns and indicator data

Year-over-year EPS growth (TTM) measures the trend of net income per share over a rolling year, allowing investors to strip away accounting adjustments and assess the real profitability of the business. Effective outsourcing of trials at Protagonist Therapeutics (PTGX) optimizes costs, which is reflected in the comparable annual growth of TTM EPS, confirming the fundamental stability and high quality of the company's assets.